New CNS-Focused Biotech Cerevance Launches With Takeda Backing

Takeda invests in CNS startup, Cerevance, as part of its externalized R&D strategy.

Human anatomy
Cerevance will focus on its portfolio of early-stage CNS compounds, including some Takeda assets • Source: Shutterstock

Cerevance – a company focused on novel therapeutics for neurological and psychiatric disorders – has launched with operations in the US and the UK, after securing investment from Takeda Pharmaceutical Co. Ltd. and Lightstone Ventures. Takeda has granted the startup its recently shuttered Cambridge, UK laboratory site to progress several preclinical and early stage assets targeting central nervous system (CNS) indications.

Cerevance, which is based on technology created in the Howard Hughes Medical Institute laboratory of Dr Nathaniel Heintz at the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.